-
ASCO 2026 | Prof. Li Mao: Ensartinib’s Global Strategy in the Intensifying ALK+ NSCLC Landscape
On-site at the 2026 ASCO Annual Meeting, the targeted therapy landscape for ALK-positive non-small cell lung cancer (NSCLC) is witnessing intense competition, with multiple frontline updates from cutting-edge studies reshaping the global dynamics. As a pioneering Chinese homegrown innovative drug making its way onto the world stage, how can ensartinib—Betta Pharmaceuticals’ proprietary ALK inhibitor—demonstrate its…
-
ASCO 2026 | Prof. Kohei Shitara: T-DXd Establishes the New Standard for Second-Line HER2-Positive Advanced Gastric Cancer, with China’s Contributions Driving Global Progress
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago from May 29 to June 2, 2026, showcased several practice-changing advances in oncology. Among the highlights, Prof. Kohei Shitara from the National Cancer Center Hospital East, Japan, presented additional health-related quality of life (HRQoL) data from the landmark DESTINY-Gastric04 trial, further demonstrating…
-
ASCO 2026 | Prof. Xiaotian Zhang and Prof. Yelena Janjigian: The DESTINY-Gastric Program Reshapes HER2-Targeted Therapy in Gastric Cancer as Chinese and U.S. Experts Discuss the Next Chapter
The landmark results of the DESTINY-Gastric04 (DG04) trial have firmly established trastuzumab deruxtecan (T-DXd) as the missing piece in second-line HER2-targeted treatment for gastric cancer. At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, the DESTINY-Gastric03 (DG03) study was also unveiled, highlighting the promising potential of T-DXd in the first-line setting. As T-DXd…
-
Precise Characterization of Transplant Prognosis: From DTA Mutation Monitoring to TP53 Aberration Stratification, Experts at EHA 2026 Discuss Changing Landscape of Myeloid Neoplasm Treatment
The 2026 European Hematology Association (EHA) Annual Meeting was grandly held in Madrid, Spain. As one of the most influential academic events in the global hematology field, the application of allo-HSCT in myeloid neoplasms remains a focus of academic debate and innovation. This specialized session, chaired by Professor Anna Sureda (Catalan Institute of Oncology, Barcelona,…
-
EHA 2026 Authoritative Release: Major Update of CLL and Richter Transformation Guidelines, Opening a New Era of Precision and Fixed-Duration Therapy
At the 2026 European Hematology Association (EHA) Annual Meeting, experts including Professor Paolo Ghia from Università Vita-Salute San Raffaele, Professor Barbara Eichhorst from the University Hospital of Cologne, and Professor Elżbieta Kalicińska from Wroclaw Medical University jointly released and interpreted the latest version of the “EHA Guidelines for the Management of Chronic Lymphocytic Leukemia (CLL)…
-
Breaking the Stalemate in CALR-Mutated Myelofibrosis: INCA033989 Demonstrates Deep Disease-Modifying Potential and Bone Marrow Morphological Improvement
At the 2026 European Hematology Association (EHA) Annual Congress, Professor Claire Harrison from Guy’s and St Thomas’ NHS Foundation Trust, London, shared the latest research data on the mutation-specific monoclonal antibody INCA033989 (hereinafter referred to as “989”) for the treatment of calreticulin (CALR)-mutated myelofibrosis (MF) patients. This study aims to evaluate the safety, tolerability, and…
-
Targeting the 8 kPa Prognostic Threshold: EBMT-EHA Thalassemia Gene Therapy Guideline Update Strengthens Precise Liver Risk Assessment
At the 2026 European Hematology Association (EHA) Annual Meeting, Professor Giuseppe De Franceschi from the University of Verona, Italy, representing the joint working group of the European Society for Blood and Marrow Transplantation (EBMT) and EHA, delivered an in-depth interpretation of the latest update to the “Guidelines for Patient Selection for Gene Therapy in Transfusion-Dependent…
-
ASCO China Voice | World’s First HOPE-07 Trial Launched: Disitamab Vedotin–Based Combination Poised to Redefine Perioperative Management of HER2-Expressing MIBC
Following the clinical success and approval of disitamab vedotin (RC48) plus toripalimab in locally advanced or metastatic urothelial carcinoma, attention has shifted toward improving outcomes for patients with muscle-invasive bladder cancer (MIBC) in the perioperative setting, where substantial unmet clinical needs remain.
Connecting Medical Expertise through Media